Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study

https://doi.org/10.1016/0165-0327(90)90081-IGet rights and content

Abstract

Antidepressant effects and unintended effects of paroxetine (30 mg/day) and clomipramine (150 mg/day) were compared in a double-blind, randomized, inpatient, fixed-dose, plasma-level-controlled study. Patients with a DSM-III diagnosis of major depressive disorder participated. After 1 week of single-blind placebo treatment 120 patients fulfilled the criterion of a Hamilton (17-item) score of ≥18 and were started on active treatment for 6 weeks. Drop-outs on paroxetine (n = 12) were largely due to lack of effect, and on clomipramine (n = 19) due to lack of effect (n = 7), adverse reactions or severe side effects (n = 10) and development of mania (n = 2). According to the protocol, non-responders (Hamilton total ≥ 16) after 4 weeks active treatment were terminated, and this occurred to 23 patients on paroxetine and four patients on clomipramine. Categorical response measures and group averages of rating scores showed a significantly better therapeutic effect of clomipramine from the second week of treatment on. These results are very similar to our earlier results with another selective serotonin reuptake inhibitor (citalopram), but generally at variance with the literature on this class of antidepressants, which, however, mostly deals with outpatient studies.

References (28)

  • A Georgotas et al.

    Comparative efficacy and safety of MAOI's versus TCA's in treating depression in the elderly

    Biol. Psychiatry

    (1986)
  • A.E Balant-Gorgia et al.

    Importance of oxidation polymorphism and levopromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

    Eur. J. Clin. Pharmacol.

    (1986)
  • P Bech et al.

    The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale

    Acta Psychiatr. Scand.

    (1980)
  • P Bech et al.

    Quantitative rating of depressive states. Correlation between clinical assessment, self rating scale (Beck's depressive inventory), and objective rati ng scale

    Acta Psychiatr. Scand.

    (1975)
  • P Bech et al.

    The WHO depression scale: relationship to the Newcastle scales

    Acta Psychiatr. Scand.

    (1980)
  • P Bech et al.

    Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-II syndromes

    Acta Psychiatr. Scand.

    (1986)
  • Beecham Laboratories (U.S.A.) Data on file, personal...
  • P Benfield et al.

    Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

    Drugs

    (1986)
  • M Bjerre et al.

    Dose-dependent kinetics of imipramine in elderly patients

    Psychopharmacology

    (1981)
  • K Br∅sen et al.

    Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics

    Eur. J. Clin. Pharmacol.

    (1986)
  • M.W.P Carney et al.

    The diagnosis of depressive syndromes and the prediction of ECT response

    Br. J. Psychiatry

    (1965)
  • J.L Claghorn

    A double blind comparison of paroxetine and placebo in the treatment of depressed outpatients

  • C Cording-Tömmel et al.

    Mianserin and maprotiline as compared to amitriptyline in severe endogenous depression

    Pharmacopsychiatry

    (1982)
  • Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study

    Psychopharmacology

    (1986)
  • Cited by (520)

    • Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies

      2018, European Neuropsychopharmacology
      Citation Excerpt :

      Moreover, MAOI can cause severe hypertensive episodes when associated with tyramine-containing foods. However, despite that the lack of severe side effects and increased treatment compliance, newer drugs did not surpass the efficacy of some TCA, such as chlomipramine (Danish University Antidepressant Group 1986, 1990). Clinical trials in research settings with selected patient populations typically yield response and remission rates of ~60% and ~40%, respectively, with standard antidepressant drugs (Tollefson and Holman, 1994; Stahl, 2000; Thase et al., 2001).

    View all citing articles on Scopus

    participating centers: 1Department of Psychiatry, Odense University, Odense, 2Departments of Psychiatry, Frederiksborg general Hospital, Hillerød, 3Department of psychiatry, Rigshospitalet, University of Copenhagen, 4Departments A and C, Psychiatric University Hospital, Århus, 5Department of Psychiatry, Frederiksberg Hospital, Frederiksberg, 6Department of Psychiatry, Bornholm General Hospital, Rønne, 7Department of Clinical Pharmacology, Odense University, Odense (Demanrk) Participating clinicians: B. Andersen1, K. Brøsen1, P. Christenen1, A. Lolk1, P. kragh-Sørensen1, S. Nielsen1, O.L. Ped 1, P. Rask1, P. bech2, H. Bjerrum2,3, L. Clemmesen2, H. Folker2, L. lauritsen2, D. Loldrup2, O.J. Rafaelsen3, K. Ødum3, U. Bartels4, E.B. Jensen4, N. Nielsen4, N. Reisby4. A. Weeke4, P. Vestergaard4, P. Videbech4, A. Amdisen4, E.M. Andersen5, S. Bøjholm6 Coordination and drug assay; L.F. Gram7, K. Brøsen7, K.B. Nielsen7 Study monitor: L. Rostrup (Ferrosan Ltd.) Steering Committee:L.F. Gram (chairman), P. Bech, P. kragh-Sørensen, O.J. Rafaelsen, N.Reisby, P. Vestergaard

    View full text